Adiponectin – Clinical Diagnostic Biomarker for Metabolic Risk Assessment


Key Benefits of the Randox Adiponectin reagent

A niche product from Randox

Randox are one of the only manufacturers to provide the adiponectin assay in an automated biochemistry format

Automated assay

Automation removed the inconvenience and time consumption associated with traditional ELISA-based testing

Wide range of Applications available

Randox Adiponectin can be used on a wide range of automated biochemistry analysers to ensure ease of programming and confidence in results

Other features of the Randox Adiponectin assay

  • Latex Enhanced Immunoturbidimetric method delivering high performance
  • Liquid ready-to-use reagents for convenience and ease-of-use
  • Extensive measuring range for measurement of clinically important results, measuring between 0.50 – 40 μg/mL
  • Complementary controls and calibrators available offering a complete testing package
  • Stable for 28 days on-board the analyser at approximately +10°C
  • Total adiponectin is measured using the Randox assay
Cat NoSizeAnalyserEasy Read
Easy Fit
AO2799R1 4 x 65ml
R2 4 x 33.5ml
RX Suzuka
RX Daytona +/Monaco
Abbott Architect
Hitachi 917/Mod P
Konelab 20i/30i/60i
Beckman Coulter AU Series

AO2999R1 2 x 15.8ml
R2 2 x 8.4ml
RX Suzuka
RX Daytona +/Monaco
Abbott Architect
Hitachi 917/Mod P
Konelab 20i/30i/60i
Beckman Coulter AU Series

AO8154R1 1 x 8.7ml
R2 1 x 8.7ml
RX Modena--

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

Clinical significance

Adiponectin is a protein hormone and is solely secreted by adipocytes, with anti-inflammatory and insulin-sensitising properties.  It plays an important role in a number of metabolic processes such as glucose regulation and fatty acid oxidation.

Adiponectin levels are inversely correlated with abdominal visceral fat (AVF) levels, which have proven to be a strong predictor of several pathologies including metabolic syndrome, type 2 diabetes mellitus (T2DM), cancers and cardiovascular disease (CVD).


Drawbacks of current T2DM risk assessment

The traditional biomarker tests used to assess T2DM risk include FPG (Fasting Plasma Glucose), OGTT (Oral Glucose Tolerance Test), and HbA1c.  However these cannot be considered a good assessment of risk as beta cell damage has already occurred, and insulin insensitivity is already underway.

Furthermore, it is widely recognised that people who are overweight are at higher risk of developing T2DM.  For more information on the causes of type 2 diabetes, please click here [external link]. However, assessing those who are overweight can be challenging.  Studies have shown that measuring waist circumference alone measures total abdominal fat reliably, but its association with visceral fat depends on visceral fat/ subcutaneous fat ratios that vary by gender and ethnicity.² Body mass index (BMI) (weight kg / height m2) is another common method of determining which patients are classed as overweight or obese, however it has limitations in measuring athletes and varies in reliability based on age, sex, and race. As such, testing adiponectin levels using the Randox assay is a much more reliable indicator of at-risk patients.


A number of key publications have advocated the testing of adiponectin in clinical settings
  1. JAMA (2009): Adiponectin Levels and the Risk of Type 2 Diabetes – a Systematic Review and Meta-Analysis³
  • A meta-analysis involving 13 prospective studies with a total of over 14,598 participants and 2,623 cases of type 2 diabetes
  • Conclusion:  higher adiponectin levels are associated with a lower risk of T2DM across diverse populations
  1. Preventative Cardiology (2015): Adiponectin, Type 2 Diabetes and Cardiovascular Risk4
  • A prospective study following 5349 randomly selected men and women from the community, without T2DM or CV disease. Plasma adiponectin was measured at study entry. Median follow-up time was 8.5 years. During follow up, 136 participants developed T2DM. Following their diagnosis, 36 of the 136 participants experienced a CV event (myocardial infarction, ischaemic stroke, or CV death).
  • Conclusions:   increasing plasma adiponectin is associated with decreased risk of T2DM and subsequently reduced risk of CV events.

The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014 (WHO, 2017)

About 422 million people worldwide have diabetes (WHO, 2017)

The prevalence of diabetes is growing most rapidly in low and middle-income countries (WHO, 2017)

…And millions more are at risk!

1 in 3 adults have prediabetes, and 9 out of 10 those with prediabetes don’t know they have it (CDC, 2017)

Diabetes is one of the leading causes of death in the world – in 2012 it was the direct cause of 1.5 million deaths (WHO, 2017)

50% of people with diabetes die of CVD (WHO, 2017)

Diabetes is the leading cause of newly diagnosed adult blindness for people between the ages of 20 and 74 (NIDDK, 2017)

  1. Menzaghi, C., Trischitta, V. and Doria, A. Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease. Perspectives in Diabetes, vol. 56, p. 1198-1209 (2007).
  2. Grundy, S. M., Neeland, I. J., Turer, A. and Vega, G. L.. Waist circumference as measure of abdominal fat compartments.  Journal of Obesity, vol. 2013, 9 pages (2013).
  3. Li, S., Shin, H. J., Ding, E. L. and van Dam, R. M. Adiponectin Levels and Risk of Type 2 Diabetes.  JAMA, vol. 302, no. 2, p. 179-188 (2009).
  4. Lindberg, S., Skov Jensen, J., Bjerre, Pedersen, S. H., Frystyk, J., Flyvbjerg, A., Galatius, S., Jeppensen, J. and Mogelvang, R. Adiponectin, type 2 diabetes and cardiovascular risk.  Preventative Cardiology, vol. 22, no. 3, p. 276-283 (2013).

Cardiology Panel

For more information or to view more reagents within the cardiology panel, please click here

Diabetes Panel

For more information or to view more reagents within the diabetes panel, please click here

Stay up-to-date with the latest Randox Reagents news & events

Clinical Laboratory Survey